MedTrace Logo

Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea

NCT00250458 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 346

Last updated 2022-02-03

Study results available
· View outcomes & findings →

Summary

Study to test the effectiveness of a marketed drug in the treatment of migraine-associated nausea.

Conditions

Interventions

DRUG

Comparator: Rizatriptan

One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.

DRUG

Comparator: Placebo

One dose matching placebo to Rizatriptan to treat one migraine attack.

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-10-31
Completion
2006-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00250458 on ClinicalTrials.gov